Breaking AI & Tech News Analyzed

The LeadHenry Slade, the 33-year-old Exeter Chiefs centre, is defying the odds both on and off the pitch. Balancing the rigorous demands of Type 1 diabetes, obsessive-compulsive disorder, and raising three young daughters, Slade is delivering some of the best rugby of his career. His recent performance against Saracens highlights not just athletic prowess but a remarkable resilience against chronic health management.Defying Age and Biology: The Saracens PerformanceDuring Exeter's 32-12 victory over Saracens, Slade showcased a rejuvenated athletic profile. The match featured a standout moment: a 40-metre sprint back to make a sensational corner-flagging tackle on Rotimi Segun, preventing a certain try. This play, combined with five successful goal-kicks, demonstrated a player still full of running and relish.Match Outcome: Exeter secured a 32-12 win at Sandy Park.Key Play: A miraculous 40-metre recovery tackle on Segun.Coach Endorsement: Dave Walder, Chiefs' attack coach, stated, “If I was picking an England team, I’d have Henry Slade in there.”The Physical Metrics: 33 and Peak ConditionSlade attributes his physical peak to advanced recovery protocols. Despite being 33, he reports feeling quicker, stronger, and fitter than ever before. His regimen includes hot and cold contrasts, saunas, ice baths, and intensive mobility work.Age Factor: Slade is 33 but claims to be in the best physical shape of his life.Recovery Methods: Uses saunas, ice baths, and stretching to maintain peak condition.Condition Prevalence: He manages Type 1 diabetes, a condition affecting 400,000 people in the UK compared to 4 million with type 2.Strategic Implications for EnglandSlade’s form reignites the debate over his England inclusion. He was omitted from the last World Cup squad and has not featured in the last five Tests. The competition for the outside centre position is fierce, with Tommy Freeman and Benhard Janse van Rensburg also in the frame. However, Slade’s left-footed kicking, silky distribution, and experience remain unique assets.Selection Status: Omitted from the last World Cup and last five Tests.Competition: Faces competition from Tommy Freeman and Benhard Janse van Rensburg.Unique Assets: Possesses left-footed kicking prowess and experience lacking in younger rivals.The Semi-Final OutlookExeter, having finished third in the regular season, faces Bath in the Premiership semi-final. Historically, no side has ever won the title having finished third, but Slade believes the team is playing “good stuff.” His ability to perform under pressure suggests he remains a pivotal figure in Exeter’s pursuit of silverware and a potential pathway back to the international stage.

What is Immunotherapy? Immunotherapies are biological treatments that harness the immune system to prevent, control and fight diseases and other conditions. The most familiar are vaccines, which train the immune system to recognise targets such as invading pathogens. Other immunotherapies boost immune responses when they are too weak, or dampen them down when they are out of control. Still others draw on engineered immune cells or lab-made antibodies to disrupt disease processes. The Evolution of Immunotherapy Efforts to prevent disease by boosting the immune system date back thousands of years, but advanced therapies for a wide range of illnesses have come to the fore in the past two decades. A global registry of clinical trials listed 1,257 trials of immunotherapies between 2006 and 2016. The figure leapt to 4,591 in the past decade. How Do Cancer Immunotherapies Work? Cancer patients have seen great benefits from immunotherapies and dozens are now approved for more than 30 types of cancer. Some tumours evade the body’s defences by switching off immune cells, but antibody-based drugs – called checkpoint inhibitors – reactivate them so they can recognise and attack the malignancies. The Future of Immunotherapy: Beyond Cancer Researchers are now testing whether existing immunotherapies can help a broader range of patients. This includes treating allergies, infections, brain diseases, and autoimmune disorders. Some of the most exciting new immunotherapies draw on recent Nobel prizewinning work on regulatory T-cells, or Tregs, which can be used to dampen down immune responses. The Potential of Tregs in Immunotherapy Tregs are unusual immune cells that stand the immune system down once the threat has been dealt with. Therapies are in the pipeline for dementia and autoimmune diseases from type 1 diabetes and rheumatoid arthritis to lupus and chronic inflammation. The potential for Tregs is vast, and researchers believe that half of all deaths have a component that is immunological.